


Patient-driven healthcare: The transformative power of H2O - Health Outcomes Observatory -



Meet Lisa



A Dutch patient with diabetes and lung cancer, who uses H2O to track the data about her health in a standardised way. She has full control over who she shares the data with and for what scope.



NATIONAL DUTCH H2O OBSERVATORY



As a result she can:



Compare her data with patients around Europe to gain a better understanding of her diseases.



Have a more effective conversation with healthcare professionals and her caregivers.



Jointly identify if her treatment is achieving the best possible outcomes, and make adjustments if needed.



The H2O patient agreement

gives Lisa full control over her data.

- ✓ She has clear options to opt in or out or share data with anyone.
- ✓ She can allow the combination of outcome data with her electronic health records or other clinical data.
- ✓ She can enable the option to share her data for research purposes.

For example:

She can choose to **share her outcomes with her clinical team** and **request her health data** from the hospital.



+ Making it easier for her clinicians to use the key information and make better decisions.

She can choose to **share her health data** in a pseudonymised way with **researchers**.



+ Resulting in information showing how well treatments work in real-life situations.

She can choose to **share her data** with her **relatives or caregivers**.



+ Improving long-term healthcare quality by sharing results and outcomes with patients.

+ Resulting in valuable information to discover and develop new medicines.

H2O data flow

- Patient data with consent
- Anonymised patient data
- Pseudonymised data



Let's make this a reality!



H2O has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945345. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and Trial Nation and JDRF. www.ih2o.europa.eu

DISCLAIMER: this infographic reflects only the author's view. Neither IMI, nor EFPIA, nor the European Commission, nor the JU are liable for any use that may be made of the information it contains.

The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It works to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI was the world's biggest public-private partnership (PPP) in the life sciences until its successor, the Innovative Health Initiative (IHI), was established in 2021. www.ih2o.europa.eu

